Thomas Jefferson University

Jefferson Digital Commons
Department of Dermatology and Cutaneous
Biology Faculty Papers

Department of Dermatology and Cutaneous
Biology

9-1-2019

Eosinophilic dermatosis of hematologic malignancy responding
to dupilumab in a patient with chronic lymphocytic leukemia.
Annie Jin
Temple University

Bobak T. Pousti
Temple University

Kevin T. Savage
Drexel University College of Medicine

Nicholas K. Mollanazar
University of Pennsylvania
Follow this and additional works at: https://jdc.jefferson.edu/dcbfp

Jason B. Lee

Thomas
Jefferson
UniversityCommons
Part of
the Dermatology

Let us know how access to this document benefits you
See next page for additional authors

Recommended Citation
Jin, Annie; Pousti, Bobak T.; Savage, Kevin T.; Mollanazar, Nicholas K.; Lee, Jason B.; and Hsu,
Sylvia, "Eosinophilic dermatosis of hematologic malignancy responding to dupilumab in a
patient with chronic lymphocytic leukemia." (2019). Department of Dermatology and Cutaneous
Biology Faculty Papers. Paper 114.
https://jdc.jefferson.edu/dcbfp/114
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been
accepted for inclusion in Department of Dermatology and Cutaneous Biology Faculty Papers by an authorized
administrator of the Jefferson Digital Commons. For more information, please contact:
JeffersonDigitalCommons@jefferson.edu.

Authors
Annie Jin, Bobak T. Pousti, Kevin T. Savage, Nicholas K. Mollanazar, Jason B. Lee, and Sylvia Hsu

This article is available at Jefferson Digital Commons: https://jdc.jefferson.edu/dcbfp/114

CASE

REPORT

Eosinophilic dermatosis of hematologic
malignancy responding to dupilumab in a
patient with chronic lymphocytic leukemia
Annie Jin, BA,a,b Bobak T. Pousti, BS,a,b Kevin T. Savage, BA,c Nicholas K. Mollanazar, MD, MBA,d
Jason B. Lee, MD,e and Sylvia Hsu, MDa
Philadelphia, Pennsylvania
Key words: chronic lymphocytic leukemia; dupilumab; EDHM; eosinophilic dermatosis of hematologic
malignancy; eosinophilic dermatosis of myeloproliferative disease; IL-4; insect biteelike eruption; insect
biteelike reaction; interleukin 4; leukemia cutis; varicella zoster.

INTRODUCTION
Leukemia cutis (LC) and eosinophilic dermatosis
of hematologic malignancy (EDHM) are rare cutaneous manifestations of hematologic malignancies.
Various therapeutic options have been reported,
with largely underwhelming responses. We present
a patient with chronic lymphocytic leukemia (CLL)
with concomitant LC and EDHM who was treated
with dupilumab.

CASE REPORT
An 81-year-old Hispanic man with CLL presented
for ‘‘sores’’ on his arms, back, and face. The patient
had been treated with acyclovir and valacyclovir for
presumed varicella zoster infection a few weeks
prior. No improvement of his rash was noted. Prior
biopsy by an outside dermatologist showed acantholysis and spongiosis concerning for pemphigus
vulgaris, but direct immunofluorescence results
were negative. The rash had improved with prednisone but recurred shortly afterward.
Physical examination showed erythematous erosions with scaling and crusting in a dermatomal
distribution on the left chest and face; a single
ulcerated nodule on the scalp; and several welldemarcated, faintly pink dermal nodules on the
back and left neck (Fig 1). Biopsy results for samples
from the left neck and back were consistent with LC
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(Fig 2), whereas biopsy results for samples from the
left chest, left sideburn, and scalp were consistent
with EDHM (Fig 3). The patient received rituximab
and chlorambucil for the LC and started a slow,
6-week prednisone taper for the EDHM, with resolution of his lesions. Once the patient was receiving less
than 10 mg of prednisone daily, his eruption quickly
flared. Repeat biopsy again confirmed EDHM. After
numerous failed attempts to wean the patient off oral
steroids, the patient was started on dupilumab offlabel, with a loading dose of 600 mg subcutaneously
followed by 300 mg once every 2 weeks. The lesions
resolved after 2 injections (Fig 4). The patient
remained clear while receiving dupilumab for more
than 6 months as his CLL was treated.

DISCUSSION
of

LC and EDHM are rare cutaneous manifestations
hematologic malignancies. Our case was

Correspondence to: Annie Jin, BA, Department of Dermatology,
Lewis Katz School of Medicine at Temple University, 1316 W
Ontario St, 1st Floor, Philadelphia, PA 19140. E-mail: Annie.Jin@
temple.edu.
JAAD Case Reports 2019;5:815-7.
2352-5126
Ó 2019 by the American Academy of Dermatology, Inc. Published
by Elsevier, Inc. This is an open access article under the CC BYNC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
https://doi.org/10.1016/j.jdcr.2019.07.026

815

816 Jin et al

JAAD CASE REPORTS

SEPTEMBER 2019

Fig 3. Superficial and deep perivascular and interstitial
dermatitis with numerous eosinophils. Original magnification, 3400.

Fig 1. Confluent erythematous macules and patches on
left chest and proximal aspect of the left arm before
treatment with dupilumab.

Fig 2. Dense, lymphocytic infiltrate composed of hyperchromatic lymphocytes, many of which coexpress CD5,
Bcl2, and CD23 on immunohistochemical staining. No
eosinophils were noted.

complicated by the presence of both lesions, which
is unusual.
LC typically presents with erythematous, firm
papules and nodules and has been reported to
have a predilection for sites of previous zoster
infection, as in our patient. Treatment is targeted at
the underlying malignancy.1
EDHM is most commonly associated with CLL, as
seen in our patient, and it often presents as pruritic,
tender nodules or papules that are erythematous and

Fig 4. After 2 doses of dupilumab.

indurated.2 Previous studies have reported inadequate responses to topical corticosteroids, systemic
antihistamines, ultraviolet B phototherapy, and interferon therapy in the majority of cases.3 Partial or
complete response to prednisone has been reported
in several studies, which was consistent with our
patient’s experience.3,4 Although some studies have
also reported positive responses with dapsone,
adverse effects ultimately resulted in discontinuation
of that drug.4
Cytokine imbalance is theorized to drive the
proliferation of malignant B cells in patients with
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EDHM, due to excessive amounts of interleukin (IL)
4 and IL-5.5 The role of IL-4 in B-cell class switching
is well established. Excess IL-4 is thought to also
drive the altered immune response with eosinophilic infiltrate seen in EDHM—as shown by lesional EDHM biopsies with prolonged eosinophil
survival in culture.3 Dupilumab is a monoclonal
antibody that occupies the shared alpha subunit
receptor site for IL-4 (IL-4a), thereby blocking the
effects of IL-4 and IL-13 signaling pathways.6 We
believe that our patient’s dramatic response to
dupilumab was due to attenuation of excessive IL4 levels that led to the development of his EDHM
lesions.
In conclusion, IL-4 dysregulation plays a role in
the development of EDHM, as evidenced by our
patient’s remarkable response to dupilumab.
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